3-cyano-4-p-tolyl-1,2,5-oxadiazole 2-oxide | 1147335-54-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-cyano-4-p-tolyl-1,2,5-oxadiazole 2-oxide
• 英文别名: 4-(4-methylphenyl)-2-oxido-1,2,5-oxadiazol-2-ium-3-carbonitrile
• CAS: 1147335-54-3
• 化学式: C₁₀H₇N₃O₂
• 分子量: 201.184
• InChiKey: WBPLAWYOUZCJBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  75.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-cyano-4-p-tolyl-1,2,5-oxadiazole 2-oxide 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 potassium carbonate 作用下， 以 四氯化碳 、 乙腈 为溶剂， 反应 3.5h， 生成 4-[4-[[[2-(cyclohexanecarbonyl)-4-oxo-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-9-yl]amino]methyl]phenyl]-2-oxido-1,2,5-oxadiazol-2-ium-3-carbonitrile
  参考文献：
  名称：

  一类1,2,5-噁二唑-2氧化物类似物、其制备方 法和用途

  摘要：

  本发明提供了一类结构如通式I所示的1,2,5‑噁二唑‑2氧化物类似物、其制备方法及用途，该类化合物具有抗血吸虫硫氧还蛋白谷胱甘肽还原酶的活性，通过阻断血吸虫细胞正常的氧化还原平衡生理代谢过程来杀灭血吸虫，可以作为治疗血吸虫病新药开发的药物先导物，为预防和治疗血吸虫病提供新的手段。

  公开号：

  CN104003954B
• 作为产物：
  描述：

  3-(4-bromophenyl)prop-2-en-1-ol 在 吡啶 、 氯化亚砜 、 盐酸羟胺 、 戴斯-马丁氧化剂 、 溶剂黄146 、 sodium nitrite 作用下， 以 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 3-cyano-4-p-tolyl-1,2,5-oxadiazole 2-oxide
  参考文献：
  名称：

  一类1,2,5-噁二唑-2氧化物类似物、其制备方 法和用途

  摘要：

  本发明提供了一类结构如通式I所示的1,2,5‑噁二唑‑2氧化物类似物、其制备方法及用途，该类化合物具有抗血吸虫硫氧还蛋白谷胱甘肽还原酶的活性，通过阻断血吸虫细胞正常的氧化还原平衡生理代谢过程来杀灭血吸虫，可以作为治疗血吸虫病新药开发的药物先导物，为预防和治疗血吸虫病提供新的手段。

  公开号：

  CN104003954B

文献信息

• Synthesis of cyanofuroxans from 4-nitrofuroxans via C C bond forming reactions
  作者：Ryosuke Matsubara、Akihiro Ando、Masahiko Hayashi

  DOI：10.1016/j.tetlet.2017.07.015

  日期：2017.8

  direct synthesis process. The optimized reaction conditions showed an excellent applicability for the synthesis of a range of 4-cyanofuroxans. 3-Cyanofuroxans, known to be thiol-mediated nitric oxide donors, could also be obtained by the thermal or photochemical isomerization of 4-cyanofuroxans. The developed cyanation of furoxans is a rare example of CC bond-forming reaction on a furoxan ring.

  描述了4-硝基呋喃烷的取代反应以制备4-氰基呋喃烷。逆反应使该取代反应复杂化，明智地选择氰化物源对于实现这种直接合成过程很重要。优化的反应条件显示出极好的适用于合成一系列4-氰基呋喃聚糖。3-氰基呋喃类，已知是硫醇介导的一氧化氮供体，也可以通过4-氰基呋喃类的热或光化学异构化获得。呋喃喃的发达氰化反应是呋喃环上形成C C键的罕见反应。
• OXADIAZOLE-2-OXIDES AS ANTISCHISTOSOMAL AGENTS
  申请人：Thomas Craig J.

  公开号：US20110207784A1

  公开（公告）日：2011-08-25

  The invention provides 1,2,5-oxadiazole-containing compounds of Formula (I), wherein R 1 , A, and R 2 are as defined herein, that are useful in treating schistosomiasis. The invention also provides a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, and a method of treating schistosomiasis in a mammal.

  该发明提供了公式（I）中含有1,2,5-噁二唑基团的化合物，其中R1、A和R2如本文所定义，可用于治疗血吸虫病。该发明还提供了一种包含药学适用载体和至少一种该发明化合物的组合物，以及一种治疗哺乳动物血吸虫病的方法。
• Structure Mechanism Insights and the Role of Nitric Oxide Donation Guide the Development of Oxadiazole-2-Oxides as Therapeutic Agents against Schistosomiasis
  作者：Ganesha Rai、Ahmed A. Sayed、Wendy A. Lea、Hans F. Luecke、Harinath Chakrapani、Stefanie Prast-Nielsen、Ajit Jadhav、William Leister、Min Shen、James Inglese、Christopher P. Austin、Larry Keefer、Elias S. J. Arnér、Anton Simeonov、David J. Maloney、David L. Williams、Craig J. Thomas

  DOI：10.1021/jm901021k

  日期：2009.10.22

  Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we recently identified as inhibitors of thioredoxin glutathione reductase (TGR), a selenocysteine-containing flavoenzyme required by the parasite to maintain proper cellular redox balance. Through systematic evaluation of the core molecular structure of this chemotype, we define the essential pharmacophore, establish a link between the nitric oxide donation and TGR inhibition, determine the selectivity for this chemotype versus related reductase enzymes, and present evidence that these agents can be modified to possess appropriate drug metabolism and pharmacokinetic properties. The mechanistic link between exogenous NO donation and parasite injury is expanded and better defined. The results of these studies verify the utility of oxadiazole-2-oxides as novel inhibitors of TGR and as efficacious antischistosomal agents.
• Synthesis of oxadiazole-2-oxide analogues as potential antischistosomal agents
  作者：Ganesha Rai、Craig J. Thomas、William Leister、David J. Maloney

  DOI：10.1016/j.tetlet.2009.01.120

  日期：2009.4

  The synthesis of several 1,2,5-oxadiazole-2-oxide (Furoxan) analogues is described herein. These compounds were prepared in an effort to probe the SAR around the phenyl substituent and oxadiazole core for our studies toward thioredoxin-glutathione reductase (TGR) inhibition and antischistosomal activity. Published by Elsevier Ltd.
• [EN] OXADIAZOLE-2-OXIDES AS ANTISCHISTOSOMAL AGENTS<br/>[FR] OXADIAZOLE-2-OXYDES EN TANT QU'AGENTS ANTISCHISTOSOMIAUX
  申请人：US HEALTH

  公开号：WO2010019772A2

  公开（公告）日：2010-02-18

  The invention provides 1,2,5-oxadiazole-containing compounds of Formula (I), wherein R1, A, and R2 are as defined herein, that are useful in treating schistosomiasis. The invention also provides a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, and a method of of treating schistosomiasis in a mammal.